|
Product Details:
Payment & Shipping Terms:
|
| CAS: | 341031-54-7 | Product Name: | Sunitinib Malate |
|---|---|---|---|
| Type: | Anti Tumor Drugs | Appearance: | White To Yellow Powder |
| Usage: | Anti Cancer | Alias: | SU 011248 |
| Assay: | 99% | Key Words: | Sunitinib Malate |
| High Light: | lab research chemicals,research chemicals |
||
Anti Tumor Drugs Sunitinib Malate Cancer Treatment API 341031-54-7 Anti Cancer
Description:
Name: 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-
Superlist Name: Sunitinib
CAS No.: 557795-19-4
Specification: 99%
Formula: C22H27FN4O2
Molecular Weight: 398.47
Density: 1.23 g/cm3
Melting Point: 189-191 °C
Boiling Point: 572.136 °C at 760 mmHg
Flash Point: 299.818 °C
Appearance: white to yellow powder
Sunitinib malate Use
Sunitinib malate plays a role in the treatment by preventing cancer cells from getting blood and nutrients needed for growth. Clinical trials show that the medicine can delay the gastrointestinal stromal tumor's growth speed, and can reduce the size of renal cell cancer.
Sunitinib malate is the first the new target drug to selectively according to multiple receptor tyrosine kinases, combined with the two function mechanism which terminate the formation of anti angiogenesis which provide blood to tumor cellss and the anti-tumor which directly attack tumor cells.
It represents a new round of the advent of targeted therapies, not only directly attack the tumor, nor have conventional chemotherapy toxicity reaction.
COA
Item of analysis |
Standard | Result of analysis | |
| Description | White to pale yellow powder | Conforms | |
| Melting piont | 215.0-227.0ºc | 219.0-220.0ºc | |
| Identification | A:IR | Conresponding to reference spectrum | Conresponding to reference spectrum |
| B :HPLC | Conresponding to reference rt | Conresponding to reference rt | |
| Loss on drying | ≤0.5% | 0.31% | |
| Residual on lgnition | ≤0.5% | 0.19% | |
| Residual solvent | Pyridine | ≤4000ppm | ND |
| DMF | ≤3000ppm | ND | |
| Chloroform | ≤4000ppm | ND | |
| Ordinary impurities | Total impurities≤2.0% | 0.30% | |
| Assay | 98.0%~101.0% | 99.7% | |
Mechanism of action
Sunitinib inhibits cellular signaling by targeting multiple receptor tyrosine kinases (RTKs).
These include all receptors for platelet-derived GF (PDGF-Rs) and vascular endothelial GF receptors (VEGFRs), which play a role in both tumor angiogenesis and tumor cell proliferation. The simultaneous inhibition of these targets therefore reduces tumor vascularization and triggers cancer cell apoptosis and thus results in tumor shrinkage.
Sunitinib also inhibits CD117 (c-KIT), the receptor tyrosine kinase that (when improperly activated by mutation) drives the majority of gastrointestinal stromal cell tumors. It has been recommended as a second-line therapy for patients whose tumors develop mutations in c-KIT that make them resistant to imatinib, or who the cannot tolerate the drug.
In addition, sunitinib binds other receptors.These include:
RET
CD114
CD135
The fact that sunitinib targets many different receptors, leads to many of its side effects such as the classic hand-foot syndrome, stomatitis, and other dermatologic toxicities.
Anti Tumor Drugs Sunitinib Malate Cancer Treatment API 341031-54-7 Anti Cancer
Contact Person: bruce
Tel: +8618874586545
